Method: Knock-in (KI) mice containing the V726A mutation or littermate controls (S129SV background) were observed without intervention or were administered an intravitreal injection of 250 ng lipopolysaccharide (LPS) in one eye and saline in the contralateral eye. Ocular inflammation was assessed histologically using a scoring system. Granulocyte populations in the blood and uveitic eye tissue were quantified by flow cytometry and immunofluorescence. Arthritis was assessed histologically and by whole body, near-infrared fluorescence imaging of inflamed regions labeled by with ProSense. Multi-plex ELISA was performed to quantify cytokine levels in uveitic eye tissue.
Result: Akin to patients with FMF, carriers with 2 copies of the mutation (i.e. KI mice) exhibit granulocytosis and arthritis that coincided with conjunctivitis. While the MEFV mutation did not predispose to spontaneous onset of uveitis, it did render KI mice markedly sensitive to LPS-induced uveitis as these mice developed an extensive pan-uveitis that was significantly worse that litter-mate controls. Interestingly, a pathergy response was observed in saline-injected KI controls. Ocular inflammation was characterized by infiltration predominantly of neutrophils and eosinophils that coincided with dilated blood vessels and hemorrhaging within the retina. Analysis of cytokine levels in uveitic eye tissue homogenates revealed a significant increase in IL-1β production compared to litter-mate controls.
Conclusion: Our data provide insight into how dysregulation of pyrin might influence intraocular inflammatory responses, and thereby result in more severe uveitis following an environmental trigger such as LPS.
Disclosure: H. L. Rosenzweig, None; J. S. Clowers, None; J. Allensworth, None; E. E. Vance, None; S. R. Planck, None; M. P. Davey, None; J. J. Chae, None; D. L. Kastner, None; J. T. Rosenbaum, Abbott Immunology Pharmaceuticals, 5, Regeneron, 5, Amgen, 5, Genentech and Biogen IDEC Inc., 2, Xoma Corporation , 5, Novartis Pharmaceutical Corporation, 2, Pfizer Inc, 5 .